These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 34143299)

  • 21. The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy.
    Kumar PA; Brosius FC; Menon RK
    Curr Diabetes Rev; 2011 Jan; 7(1):50-5. PubMed ID: 21067510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency.
    Skjaerbaek C; Frystyk J; Kaal A; Laursen T; Møller J; Weeke J; Jørgensen JO; Sandahl Christiansen J; Orskov H
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):25-33. PubMed ID: 10651750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
    Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus.
    Mohamed-Ali V; Pinkney J
    Treat Endocrinol; 2002; 1(6):399-410. PubMed ID: 15832492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of growth hormone in chronic heart failure. Therapeutic implications.
    Volterrani M; Manelli F; Cicoira M; Lorusso R; Giustina A
    Drugs; 2000 Oct; 60(4):711-9. PubMed ID: 11085197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1,25 dihydroxyvitamin D3 production in healthy man.
    Bianda T; Hussain MA; Glatz Y; Bouillon R; Froesch ER; Schmid C
    J Intern Med; 1997 Feb; 241(2):143-50. PubMed ID: 9077371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Childhood and adolescent diabetes.
    Dunger DB; Regan FM; Acerini CL
    Endocr Dev; 2005; 9():107-120. PubMed ID: 15879693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of recombinant human growth hormone on serum Klotho and fibroblast growth factor 23 in children with idiopathic short stature].
    Dong HH; Li MM; Sun M; Zhou R; Zhang XY; Cheng YY
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Nov; 25(11):1143-1149. PubMed ID: 37990459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice.
    Flyvbjerg A; Bennett WF; Rasch R; Kopchick JJ; Scarlett JA
    Diabetes; 1999 Feb; 48(2):377-82. PubMed ID: 10334317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice.
    Segev Y; Landau D; Rasch R; Flyvbjerg A; Phillip M
    J Am Soc Nephrol; 1999 Nov; 10(11):2374-81. PubMed ID: 10541297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired renal growth hormone JAK/STAT5 signaling in chronic kidney disease.
    Wiezel D; Assadi MH; Landau D; Troib A; Kachko L; Rabkin R; Segev Y
    Nephrol Dial Transplant; 2014 Apr; 29(4):791-9. PubMed ID: 24463190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess.
    Ciresi A; Giordano C
    Growth Horm IGF Res; 2017 Apr; 33():35-42. PubMed ID: 28372721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease.
    Flyvbjerg A; Landau D; Domene H; Hernandez L; Grønbaek H; LeRoith D
    Metabolism; 1995 Oct; 44(10 Suppl 4):67-71. PubMed ID: 7476314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The growth hormone/insulin-like growth factor axis in the kidney: aspects in relation to chronic renal failure.
    Flyvbjerg A
    J Pediatr Endocrinol; 1994; 7(2):85-92. PubMed ID: 8061765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Klotho and the Growth Hormone/Insulin-Like Growth Factor 1 Axis: Novel Insights into Complex Interactions.
    Rubinek T; Modan-Moses D
    Vitam Horm; 2016; 101():85-118. PubMed ID: 27125739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Safety and Efficacy of Growth Hormone Therapy by IGF-1 Z Score in Children with Short Stature.
    Liu HJ; Wang LH; Chen L
    Adv Ther; 2019 Sep; 36(9):2374-2383. PubMed ID: 31301056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acromegalic Cardiomyopathy: An Entity on its own? The Effects of GH and IGF-I Excess and Treatment on Cardiovascular Risk Factors.
    Wolf P; Maione L; Kamenický P; Chanson P
    Arch Med Res; 2023 Dec; 54(8):102921. PubMed ID: 38040526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.